GlaxoSmithKline (GSK) has submitted its albiglutide once-weekly injection for type 2 diabetes to European regulators.
If approved the biologic treatment, which was submitted for US approval in January, will be marketed as Eperzan.
Albiglutide is, along with lupus treatment Benlysta and heart disease drug darapladib, one of a trio of drugs GSK has developed with Human Genome Sciences.
The Economic Alliance of Greater Baltimore (EAGB) and BioHealth Innovation (BHI) in collaboration with the Baltimore Business Journal are proud to announce the publication of the Central Maryland BioHealth Entrepreneur’s Resource and Financing Guide.
This Guide will be a compendium of resources to BioHealth innovators and entrepreneurs working to start and grow new companies in the region. A wealth of resources exists in Maryland to support emerging BioHealth companies, however, they are not always readily accessible or captured in one place. The Guide will compile information on financial resources, university facilities and programs, economic development programs, and existing federal laboratory facilities and programs and how to work with them.
Personalized medicine — the ability to tailor therapies to patients’ individual genetic characteristics — has long been the holy grail of the life sciences industry. The effort has produced a string of recent successes, including a host of drugs targeted to people with specific genetic profiles, the European approval of the world’s first gene therapy treatment, and a much-heralded leukemia treatment pioneered at Children’s Hospital of Philadelphia (CHOP) that uses tweaked versions of patients’ own cells to eliminate their cancer. While these advances are certainly exciting for patients, they raise a host of ethical, legal and financial challenges that people working in the field will need to address before personalized medicine can become a thriving business.
The challenges are so great, contends Wharton health care management professor Ezekiel J. Emanuel, that claims of a renaissance in medicine brought on by individualized approaches often seem hyperbolic. “Before we buy into this, we need to remember that almost every evaluation of what drives health care costs up points to new technologies,” says Emanuel, who is also a professor of medical ethics and health policy at Penn’s Perelman School of Medicine. “We need to be skeptical. We need to see the data before people buy into the idea that personalized medicine is going to produce cost savings and be so much better for the system.”
The University of Maryland, College Park has cracked the top 100 global reputation ranking by a publication based in the United Kingdom, The Washington Post reported.
Times Higher Education shows that UMd. is in a group ranked 91-100, in a class with Monash University in Australia, Lund in Sweden, Bristol in the U.K., the Free University of Berlin and Texas A&M. The rankings were based on surveys of academics around the world. Johns Hopkins, in Baltimore, ranked No. 19, the highest from the local region. Harvard University was ranked No. 1.
NANOMEDICINES: CHARTING A ROADMAP TO COMMERCIALIZATION
On 6-7 March 2013, the Nanomedicines Alliance will be holding a Industry Symposium: Charting a Road to Commercialization. The Symposium will address:
through podium presentations, breakouts sessions and poster sessions.
President & CEO, Altimmune, Inc.
William “Bill” Enright joined Vaxin in June 2008 and currently serves as a Director, President & CEO. Prior to joining Vaxin, Mr. Enright spent six years with GenVec, Inc. with increasing responsibilities including the Head of Business Development. Mr. Enright was responsible for helping to build GenVec’s vaccine business including approximately $140M of funding for vaccine related initiatives and moving four vaccines into clinical development. Mr. Enright brings more than 23 years of experience in a variety of positions within the life science/biotech industry, including time as a consultant, a bench scientist and 12 years with Life Technologies, Corp. (previously Invitrogen), working in various senior level licensing, business management, manufacturing and research roles. Mr. Enright received a Master of Arts in Molecular Biology from SUNY at Buffalo and a Master of Science in Business Management from Johns Hopkins University.
Associate Vice President for Research and Economic Development, UMD
Director of Corporate Relations, UMD
Brian Darmody is responsible for developing projects, funding opportunities, and policies to support partnerships with private and government sectors. Previously he was the University’s director of state and federal relations in the President’s Office, and served in the legal counsel’s office. He serves on national and state boards, including Fruanhofer USA, National Association of Seed and Venture Funds, Maryland Venture Authority, the Technology Council of Maryland, Maryland Space Business Roundtable and is past President of the Association of University Research Parks.He has served on the staff for the U.S. House of Representatives, the U.S. Health Care Financing Administration Office of Attorney-Advisor, and the Maryland General Assembly. He holds an undergraduate degree from the University of Maryland and Juris Doctor from the University of Baltimore.
Partner
NEA
Sara Nayeem, M.D. is a Principal with New Enterprise Associates, a diversified venture capital firm with $13B in committed capital. Sara joined NEA’s healthcare team in January 2009 and focuses on investments in biopharmaceutical companies. She serves on the boards of Mersana and Cydan and as a board observer for Epizyme, Omthera and Zyngenia. She has also been involved in NEA’s investments in Tesaro, Prosensa, and 3-V Biosciences. Prior to joining NEA, Sara was an Associate with Merrill Lynch’s Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on numerous mergers, acquisitions and financing transactions. Previously, she worked as an Investment Banking Analyst at Morgan Stanley. She has conducted basic science research in mammalian cardiac development and clinical research in age-related macular degeneration. Sara concurrently earned her M.D. (cum laude) and MBA from Yale University, where she was a Yale MBA Scholar. She received her AB (magna cum laude) in Biological Sciences from Harvard University.
Big news was made at HIMSS13 on Monday when, in an unprecedented collaboration, some health IT heavy-hitters joined forces in an effort to push the needle on interoperability.
In announcing the launch of the CommonWell Health Alliance, executives from Cerner, McKesson, Allscripts, athenahealth, Greenway and RelayHealth touted what they say is a first-of-its-kind organization: a collaboration of rival vendors, uniting to enable care integration and data liquidity.
NOW IN ITS 7th YEAR!
University Startups Showcase and Conference 2013
March 20-22, 2013
Washington Convention Center, Washington, D.C.
“Corporate Venture Capital and University Startups: An Open Innovation Paradigm”
GETTING YOUR UNIVERSITY STARTUP FUNDED
2 WEEKS LEFT
REGISTRATION CLOSES: Friday March 15, 2013
(no onsite registrations)
[or go to http://www.ncet2.org/index.php?option=com_content&view=article&id=543]
